SNCA and glioblastoma: Finally, to assess the therapeutic impact of α-synuclein treatment in vivo, we allografted a murine model of GBM (GL261) overexpressing either a control (EV) or an α-syn vector in wild-type immunocompetent mice (Fig. 6A).